They’ve Got Next: The 40 Under 40 - Aaron Gruber of Cravath

Please describe two of your most substantial, recent wins in practice.
For over ten years, I’ve advised Mylan and now Viatris, helping the company navigate multiple transformative transactions. In 2019 and 2020, I represented Mylan in its $50 billion combination with Upjohn, Pfizer’s off-patent branded and generic medicines business, to form Viatris. The deal was very fast-moving and exceptionally complicated, involving a cross-border public company merger and a carve-out structured as a Reverse Morris Trust transaction.

I’m also currently representing Viatris in the pending $3.335 billion combination of its biosimilars portfolio with India-based Biocon Biologics. Like the Mylan/Upjohn combination, this ...